Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, alectinib (Alecensa®) cannot be endorsed for use within NHS Wales as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer previously treated with crizotinib. |
||
|
||
Medicine details |
||
| Medicine name | alectinib (Alecensa®) | |
| Formulation | 150 mg hard capsule | |
| Reference number | 2385 | |
| Indication | Monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer previously treated with crizotinib. |
|
| Company | Roche Products Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 25/05/2017 | |